Skip to main content

Table 1 Socio-demographic and clinical variables of the 114 patients with disability

From: Self-reported disability in women with fibromyalgia from a tertiary care center

 

Mild (n = 13)

Moderate (n = 54)

Severe (n = 47)

Total (n = 114)

P value

Size effect

Age in years

48.2 ± 5.9

49.9 ± 7.2

46.8 ± 6.4

48.4 ± 6.8

0.07

0.02a

Years of education

10 ± 3.5

10.2 ± 3.6

10.1 ± 3.2

10.1 ± 3.4

0.98

0.01a

Time since onset of pain (months)

48 (24)

48 (64)

36 (42)

48 (60)

0.22

0.02b

Time since FM diagnosis (months)

36 (46)

34 (36)

12 (36)

24 (42)

0.08

0.03b

Body mass index

29.1 ± 4.5

28.4 ± 3.1

28.9 ± 3.7

28.7 ± 3.5

0.72

0.01a

Pain Intensity

5.0 ± 2.3

6.2 ± 2.1

7.3 ± 1.6

6.5 ± 2.1

< 0.001

0.12a

Number of drugs

2.3 ± 1.1

2.12 ± 1.2

2.08 ± 1.2

2.1 ± 1.2

0.85

0.01a

Pharmacological treatment

11 [84.6]

49 [90.7]

39 [82.9]

99 [86.8]

0.49

–

 Celecoxib

5 [38.4]

21 [38.8]

9 [19.1]

35 [30.7]

0.08

 

 Nonsteroidal anti-inflammatory drugs

3 [23.0]

9 [16.6]

13 [27.6]

25 [21.9]

0.41

 

 Pregabalin or Gabapentin

6 [46.1]

30 [55.5]

24 [51.0]

60 [52.6]

0.79

 

 Antidepressants

9 [69.2]

27 [50.0]

29 [61.7]

65 [57.0]

0.31

 

 Tramadol-acetaminophen

5 [38.4]

19 [35.1]

13 [27.6]

37 [32.4]

0.64

 

 Benzodiazepines

0 [0]

7 [12.9]

4 [8.5]

11 [9.6]

0.34

 

 Quetiapine

0 [o]

0 [o]

2 [4.2]

2 [1.7]

0.23

 

Medication adherence

 Non-pharmacological treatment

2 [15.3]

5 [9.2]

8 [17.0]

15 [13.0]

0.35

 

 Adherent

5 [38.4]

26 [48.1]

17 [36.1]

48 [42.1]

  

 Non-adherent

2 [15–3]

19 [35.1]

17 [36.1]

38 [33.0]

  

 Unknown

4 [30.7]

4 [7.4]

5 [10.6]

13 [11.3]

  
  1. Data. Mean ± Standard deviation; median (interquartile range); Frequency [percent]
  2. Interpretation. a Omega squared = 0.01–0.059 is a low association. 0.06–0.13 is a medium association. ≥0.14 is a large association. b Epsilon squared